CH675683A5 - - Google Patents
Download PDFInfo
- Publication number
- CH675683A5 CH675683A5 CH1730/88A CH173088A CH675683A5 CH 675683 A5 CH675683 A5 CH 675683A5 CH 1730/88 A CH1730/88 A CH 1730/88A CH 173088 A CH173088 A CH 173088A CH 675683 A5 CH675683 A5 CH 675683A5
- Authority
- CH
- Switzerland
- Prior art keywords
- theophylline
- phytocolloid
- pharmaceutical preparation
- solution
- galactose
- Prior art date
Links
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 89
- 229960000278 theophylline Drugs 0.000 claims description 43
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 239000000084 colloidal system Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 4
- 241001474374 Blennius Species 0.000 claims description 4
- 241000195493 Cryptophyta Species 0.000 claims description 4
- 239000007791 liquid phase Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- WZYRMLAWNVOIEX-MOJAZDJTSA-N (2s)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyacetaldehyde Chemical compound O=C[C@@H](O)[C@@H]1OC[C@H](O)[C@H]1O WZYRMLAWNVOIEX-MOJAZDJTSA-N 0.000 claims description 3
- DCQFFOLNJVGHLW-UHFFFAOYSA-N 4'-Me ether-Punctatin+ Natural products O1C(O)C(O)C2OCC1C2O DCQFFOLNJVGHLW-UHFFFAOYSA-N 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 3
- WZYRMLAWNVOIEX-UHFFFAOYSA-N cinnamtannin B-2 Natural products O=CC(O)C1OCC(O)C1O WZYRMLAWNVOIEX-UHFFFAOYSA-N 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000000416 hydrocolloid Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 239000000047 product Substances 0.000 description 22
- 230000036470 plasma concentration Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 230000002459 sustained effect Effects 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
- 229940011411 erythrosine Drugs 0.000 description 2
- 235000012732 erythrosine Nutrition 0.000 description 2
- 239000004174 erythrosine Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229960004674 theophylline anhydrous Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000004327 Paroxysmal Dyspnea Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- IDAGXRIGDWCIET-SDFKWCIISA-L disodium;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IDAGXRIGDWCIET-SDFKWCIISA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000012731 long-acting form Substances 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES85547013A ES8608890A1 (es) | 1985-09-16 | 1985-09-16 | Preparado farmaceutico liquido a base de teofilina de efec- tos retardados y procedimiento para su obtencion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH675683A5 true CH675683A5 (enExample) | 1990-10-31 |
Family
ID=8489818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1730/88A CH675683A5 (enExample) | 1985-09-16 | 1988-05-06 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0343306A1 (enExample) |
| CH (1) | CH675683A5 (enExample) |
| ES (1) | ES8608890A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2068154B1 (es) * | 1993-07-13 | 1995-11-16 | Cantabria Ind Farmaceutica Sa | Nuevas formulaciones analgesicas con amplio intervalo de accion. |
| DE602005007319D1 (de) * | 2005-02-17 | 2008-07-17 | Jordanian Pharmaceutical Mfg | Zubereitung zur kontinuierlichen Arzneimittelfreisetzung Chitosan enthaltend |
-
1985
- 1985-09-16 ES ES85547013A patent/ES8608890A1/es not_active Expired
-
1988
- 1988-05-06 CH CH1730/88A patent/CH675683A5/fr not_active IP Right Cessation
- 1988-05-25 EP EP88500049A patent/EP0343306A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0343306A1 (en) | 1989-11-29 |
| ES547013A0 (es) | 1986-09-01 |
| ES8608890A1 (es) | 1986-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2672961B1 (fr) | Granules effervescents d'acide gamma-hydroxybutyrique | |
| EP0757911B1 (fr) | Nouvelles formulations galéniques du fénofibrate et leurs applications | |
| FR2629716A1 (fr) | Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique | |
| WO2003045166A1 (fr) | Capsule a solubilisation et liberation du contenu rapides | |
| FR2630912A1 (fr) | Composition permettant d'administrer un medicament sous forme de gelules, d'une poudre ou d'un liquide | |
| WO2010055260A1 (fr) | Nouvelle composition à base d'acide gamma-hydroxybutyrique | |
| EP0318398B1 (fr) | Forme à libération prolongée du diltiazem et son médicament ainsi obtenu | |
| CA2342742A1 (fr) | Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications | |
| FR2602141A1 (fr) | Composition pharmaceutique a activite analgesique contenant de l'ibuprofene comme principe actif | |
| EP0282698B1 (fr) | Procédé pour la préparation d'un produit retard-contenant du diltiazem pour une administration journalière unique | |
| WO2008068276A1 (en) | Soft gelatin capsules comprising acetylsalicylic acid | |
| EP0196434B1 (fr) | Procédé pour la préparation d'une composition à base d'un principe actif de faible hydrosolubilité finement divisé | |
| FR2539989A1 (fr) | Medicament a liberation programmee associant l'acide acetylsalicylique a la dihydroergotamine | |
| FR2551975A1 (fr) | Medicament a action antiarythmique a base de lappaconitine | |
| EP1009406B1 (fr) | Composition pharmaceutique pour l'administration de thiocolchicoside a travers la muqueuse buccale | |
| WO2015140747A1 (fr) | Utilisation d'une composition vétérinaire à base de torasémide pour une administration à faible dose | |
| EP0412877A1 (fr) | Nouvelle forme galénique orale améliorant la biodisponibilité | |
| BE1000087A3 (fr) | Compositions pharmaceutiques contenant de la vinburnine et leur procede de preparation. | |
| EP0066505B1 (fr) | Préparation pharmaceutique de "naftidrofuryl" à libération contrôlée | |
| EP0433275B1 (fr) | Composition a base de mucopolysaccharides hepariniques, active par voie orale | |
| FR2494113A1 (fr) | Nouvelle association medicamenteuse a base d'acide l-aspartique et de l-arginine | |
| EP0343306A1 (en) | Liquid pharmaceutical preparation based on theophylline with a retarding effect, and process for producing it | |
| FR2952824A1 (fr) | Composition antidiabetique contenant un extrait vegetal d'englerina lecardii | |
| BE856652A (fr) | Composition pharmaceutique pour le traitement des troubles du sommeil | |
| FR2477875A1 (fr) | Nouveaux produits a base de vincamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |